DNLI News and Press, Denali Therapeutics Inc. From 09/15/25

2025-09-15 20:21:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2025. The 13F portfolio value in...

2025-09-09 02:31:20 ET Denali Therapeutics Inc. (DNLI) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT... Read the full article on Seeking Alpha For further details see: Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Ann...

2025-08-11 16:41:20 ET More on Denali Therapeutics Denali Therapeutics: Navigating Through Recent Setbacks Seeking Alpha’s Quant Rating on Denali Therapeutics Historical earnings data for Denali Therapeutics Financial information for Denali Therapeutic...

Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval path for Sanfilippo syndrome Type A aligned with FDA; Phase 1/2 study nearing completion of enro...

Leatt Corp (LEAT) is expected to report for Q2 2025 MDU Resources Group Inc. (Holding Company) (MDU) is expected to report $0.13 for Q2 2025 Video Display Corp. (VIDE) is expected to report for quarter end 2025-05-31 Alarm.com Holdings Inc. (ALRM) is expected to report $0.38 for Q2 20...

Denali Therapeutics Inc. (DNLI) is expected to report $-0.74 for Q2 2025

2025-07-07 18:00:33 ET Denali Therapeutics ( Nasdaq: DNLI ) announced that the FDA has accepted its Biologics License Application (BLA) for tividenofusp alfa and granted the therapy Priority Review for the treatment of Hunter syndrome, a rare and progressive genetic disorder. Th...

FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval Tividenofusp alfa is designed to deliver missing enzyme to entire body and cross blood-brain barrier into the brain Tividenofusp alfa leads company’s broader TransportVehicleȒ...

2025-06-26 14:36:06 ET Today, I am putting Denali Therapeutics Inc. ( DNLI ) in the spotlight for the first time in 2025. My last article on this intriguing but complex clinical stage biotech concern was in August 2024. I concluded that piece by saying was it was probabl...

2025-06-17 21:14:09 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers' 13F stock portfolio on a quarterly basis. It is based on Baker Brothers' regulatory 13F Form filed on 05/15/2025. The 13F portfolio value decreased from $...